TY  - BOOK
AU  - Sugarbaker, Paul H
AU  - Yan, Tristan D
TI  - Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
SN  - 0732-183X
PY  - 2012///
KW  - *Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]
KW  - *Appendiceal Neoplasms/pa [Pathology]
KW  - *Hyperthermia, Induced/mt [Methods]
KW  - *Peritoneal Neoplasms/sc [Secondary]
KW  - *Peritoneal Neoplasms/th [Therapy]
KW  - *Pseudomyxoma Peritonei/dt [Drug Therapy]
KW  - *Pseudomyxoma Peritonei/su [Surgery]
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Combined Modality Therapy
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Injections, Intraperitoneal
KW  - Male
KW  - Middle Aged
KW  - Peritoneal Neoplasms/dt [Drug Therapy]
KW  - Peritoneal Neoplasms/mo [Mortality]
KW  - Peritoneal Neoplasms/su [Surgery]
KW  - Pseudomyxoma Peritonei/mo [Mortality]
KW  - Survival Rate
KW  - Young Adult
KW  - MedStar Washington Hospital Center
KW  - Washington Cancer Institute
KW  - Surgery/General Surgery
KW  - Journal Article
KW  - Multicenter Study
KW  - Research Support, Non-U.S. Gov't
N1  - Available online from MWHC library: 1999 - present, Available in print through MWHC library: 1999 - 2008
N2  - CONCLUSION: The combined modality strategy for PMP may be performed safely with acceptable morbidity and mortality in a specialized unit setting with 63% of patients surviving beyond 10 years. Minimizing nondefinitive operative and systemic chemotherapy treatments before definitive cytoreduction may facilitate the feasibility and improve the outcome of this therapy to achieve long-term survival. Optimal cytoreduction achieves the best outcomes; PATIENTS AND METHODS: A retrospective multi-institutional registry was established through collaborative efforts of participating units affiliated with the Peritoneal Surface Oncology Group International; PURPOSE: Pseudomyxoma peritonei (PMP) originating from an appendiceal mucinous neoplasm remains a biologically heterogeneous disease. The purpose of our study was to evaluate outcome and long-term survival after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) consolidated through an international registry study; RESULTS: Two thousand two hundred ninety-eight patients from 16 specialized units underwent CRS for PMP. Treatment-related mortality was 2% and major operative complications occurred in 24% of patients. The median survival rate was 196 months (16.3 years) and the median progression-free survival rate was 98 months (8.2 years), with 10- and 15-year survival rates of 63% and 59%, respectively. Multivariate analysis identified prior chemotherapy treatment (P < .001), peritoneal mucinous carcinomatosis (PMCA) histopathologic subtype (P < .001), major postoperative complications (P = .008), high peritoneal cancer index (P = .013), debulking surgery (completeness of cytoreduction [CCR], 2 or 3; P < .001), and not using HIPEC (P = .030) as independent predictors for a poorer progression-free survival. Older age (P = .006), major postoperative complications (P < .001), debulking surgery (CCR 2 or 3; P < .001), prior chemotherapy treatment (P = .001), and PMCA histopathologic subtype (P < .001) were independent predictors of a poorer overall survival
UR  - http://dx.doi.org/10.1200/JCO.2011.39.7166
ER  -